FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2112613728> ?p ?o ?g. }

• W2112613728 endingPage "709" @default.
• W2112613728 startingPage "702" @default.
• W2112613728 abstract "BackgroundPeri-operative chemotherapy and surgery is a standard treatment of localised oesophagogastric adenocarcinoma; however, the outcomes remain poor.Patients and methodsST03 is a multicentre, randomised, phase II/III study comparing peri-operative ECX with or without bevacizumab (ECX-B). The primary outcome measure of phase II (n = 200) was safety, specifically gastrointestinal (GI) perforation rates and cardiotoxicity.ResultsTwo hundred patients were randomised between October 2007 and April 2010. Ninety-one/101 (90%) ECX and 86/99 (87%) ECX-B patients completed pre-operative chemotherapy; 7 ECX and 9 ECX-B patients stopped due to toxicity. Gastrointestinal perforations (3 ECX, 1 ECX-B), cardiac events (1 ECX, 4 ECX-B) and venous thromboembolic events (VTEs, 8 ECX, 7 ECX-B) were uncommon. Arterial thromboembolic events (ATEs, myocardial infarction (MI) or cerebrovascular accident) were more frequent with ECX-B (5 versus 1 with ECX). Delayed wound healing, anastomotic leaks and GI bleeding rates were similar.More asymptomatic left ventricular ejection fraction (LVEF) falls (≥15% and/or to <50%) occurred with ECX-B (21.2% versus 11.1% with ECX). Clinically significant falls (≥10% to below lower limit of normal, LLN) occurred in (15.3%) and (8.9%) respectively, with no associated cardiac failure (median 22 months follow-up).ConclusionsAddition of bevacizumab to peri-operative ECX chemotherapy is feasible with acceptable toxicity and no negative impact on surgical outcomes." @default.
• W2112613728 created "2016-06-24" @default.
• W2112613728 creator A5003890551 @default.
• W2112613728 creator A5005391044 @default.
• W2112613728 creator A5010740611 @default.
• W2112613728 creator A5010914696 @default.
• W2112613728 creator A5011703751 @default.
• W2112613728 creator A5016547488 @default.
• W2112613728 creator A5016742379 @default.
• W2112613728 creator A5017492004 @default.
• W2112613728 creator A5023188445 @default.
• W2112613728 creator A5037541807 @default.
• W2112613728 creator A5040325815 @default.
• W2112613728 creator A5042298510 @default.
• W2112613728 creator A5045865889 @default.
• W2112613728 creator A5056345420 @default.
• W2112613728 creator A5058562981 @default.
• W2112613728 creator A5062851652 @default.
• W2112613728 creator A5065399068 @default.
• W2112613728 creator A5065638223 @default.
• W2112613728 creator A5067378114 @default.
• W2112613728 creator A5080168198 @default.
• W2112613728 creator A5084931744 @default.
• W2112613728 creator A5091438528 @default.
• W2112613728 date "2013-03-01" @default.
• W2112613728 modified "2023-10-15" @default.
• W2112613728 title "Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report" @default.
• W2112613728 cites W1967600348 @default.
• W2112613728 cites W2013865180 @default.
• W2112613728 cites W2033597946 @default.
• W2112613728 cites W2060447671 @default.
• W2112613728 cites W2096134439 @default.
• W2112613728 cites W2098114704 @default.
• W2112613728 cites W2101099004 @default.
• W2112613728 cites W2112062992 @default.
• W2112613728 cites W2113122060 @default.
• W2112613728 cites W2113818241 @default.
• W2112613728 cites W2115072149 @default.
• W2112613728 cites W2117188579 @default.
• W2112613728 cites W2122574381 @default.
• W2112613728 cites W2125447919 @default.
• W2112613728 cites W2125857654 @default.
• W2112613728 cites W2127565981 @default.
• W2112613728 cites W2135947389 @default.
• W2112613728 cites W2139927762 @default.
• W2112613728 cites W2143743735 @default.
• W2112613728 cites W2143809951 @default.
• W2112613728 cites W2146834306 @default.
• W2112613728 cites W2149347983 @default.
• W2112613728 cites W2155104309 @default.
• W2112613728 cites W2155167083 @default.
• W2112613728 cites W2157769714 @default.
• W2112613728 cites W2158118791 @default.
• W2112613728 cites W2162731664 @default.
• W2112613728 doi "https://doi.org/10.1093/annonc/mds533" @default.
• W2112613728 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23108952" @default.
• W2112613728 hasPublicationYear "2013" @default.
• W2112613728 type Work @default.
• W2112613728 sameAs 2112613728 @default.
• W2112613728 citedByCount "65" @default.
• W2112613728 countsByYear W21126137282013 @default.
• W2112613728 countsByYear W21126137282014 @default.
• W2112613728 countsByYear W21126137282015 @default.
• W2112613728 countsByYear W21126137282016 @default.
• W2112613728 countsByYear W21126137282017 @default.
• W2112613728 countsByYear W21126137282018 @default.
• W2112613728 countsByYear W21126137282019 @default.
• W2112613728 countsByYear W21126137282020 @default.
• W2112613728 countsByYear W21126137282021 @default.
• W2112613728 countsByYear W21126137282022 @default.
• W2112613728 countsByYear W21126137282023 @default.
• W2112613728 crossrefType "journal-article" @default.
• W2112613728 hasAuthorship W2112613728A5003890551 @default.
• W2112613728 hasAuthorship W2112613728A5005391044 @default.
• W2112613728 hasAuthorship W2112613728A5010740611 @default.
• W2112613728 hasAuthorship W2112613728A5010914696 @default.
• W2112613728 hasAuthorship W2112613728A5011703751 @default.
• W2112613728 hasAuthorship W2112613728A5016547488 @default.
• W2112613728 hasAuthorship W2112613728A5016742379 @default.
• W2112613728 hasAuthorship W2112613728A5017492004 @default.
• W2112613728 hasAuthorship W2112613728A5023188445 @default.
• W2112613728 hasAuthorship W2112613728A5037541807 @default.
• W2112613728 hasAuthorship W2112613728A5040325815 @default.
• W2112613728 hasAuthorship W2112613728A5042298510 @default.
• W2112613728 hasAuthorship W2112613728A5045865889 @default.
• W2112613728 hasAuthorship W2112613728A5056345420 @default.
• W2112613728 hasAuthorship W2112613728A5058562981 @default.
• W2112613728 hasAuthorship W2112613728A5062851652 @default.
• W2112613728 hasAuthorship W2112613728A5065399068 @default.
• W2112613728 hasAuthorship W2112613728A5065638223 @default.
• W2112613728 hasAuthorship W2112613728A5067378114 @default.
• W2112613728 hasAuthorship W2112613728A5080168198 @default.
• W2112613728 hasAuthorship W2112613728A5084931744 @default.
• W2112613728 hasAuthorship W2112613728A5091438528 @default.
• W2112613728 hasBestOaLocation W21126137281 @default.
• W2112613728 hasConcept C126322002 @default.
• W2112613728 hasConcept C141071460 @default.
• W2112613728 hasConcept C2776694085 @default.

• next